Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma

Istituto Clinico Humanitas88 enrolled

Overview

The study is aimed to evaluate efficacy and safety of re-irradiation for patients with recurrent high grade gliomas after other treatment.

Investigators designed this study of a re-irradiation with single radiosurgery or hypofractionated intensity modulated radiation therapy (IMRT) with or without temozolomide. Objective of the study is evaluating efficacy and safety of re-irradiation for patients with recurrent high grade gliomas after other treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Recurrent High Grade Glioma

Interventions

IMRT with or without radiosensitive therapyRADIATION

Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc

Radiosensitive therapyDRUG

Radiosensitive therapy with Temozolomide

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years * Karnosky performance status (KPS) ≥70 * Patients aged \>70 years with KPS ≥80 * Histopathologically confirmed grade III-IV glioma * Estimated survival ≥ 3 months * Any Tumor volume * Unifocal tumor * Interval time from previous radiotherapy ≥ 6mesi * Normal liver, Kidney and bone marrow function * Written informed consent Exclusion Criteria: * KPS \< 70 * Multifocal tumor * Other primary cancer * Pregnant women

Locations (1)

Istituto Clinico Humanitas

Rozzano, Milan, Italy

Outcomes

Primary Outcomes

Progression free of participants

Time frame: 4 years

Overall survival of participants

Time frame: 4 years

Secondary Outcomes

Incidence of radionecrosis

Time frame: 3 months

Questionnaire assessment of neurocognitive function

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.